This research study is currently not recruiting patients.

PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: medulloblastoma | pineoblastoma
  • Age: Between 3 - 21 Years
  • Gender: Male or Female
Inclusion Criteria
Histologically confirmed diagnosis of medulloblastoma
Meets 1 of the following criteria: M0 medulloblastoma with > 1.5 cm^2 residual tumor, M+ medulloblastoma, M0 or M+ supratentorial PNET (including pineoblastoma), Diffusely anaplastic medulloblastoma with any M-stage or residual tumor
Must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days
Karnofsky performance status (PS) 30-100% (for patients > 16 years of age) OR Lansky PS 30-100% (for patients ? 16 years of age)
Life expectancy > 8 weeks
Exclusion Criteria
pregnant or nursing


Not Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.